AviadoBio
June 23, 2026
Theater 3
Type: Company Presentation
Focus Area:
Cell and Gene Therapy and Genome Editing
AviadoBio is on a mission to relentlessly chase cures by developing and translating groundbreaking science and precision delivery into life-changing medicines across neurodegenerative diseases. Built on deep neuroscience expertise, AviadoBio is developing targeted, one-time gene therapies to precisely deliver genetic medicines to disease-relevant cells and pathways within the nervous system, restoring function and hope through advanced science. Our proprietary platforms, including intrathalamic and vMiX™ RNA silencing system, plus expertise in intravitreal, and blood-brain barrier (BBB)-penetrant delivery approaches, enable precise, durable therapeutic expression across complex neural systems such as the brain and retina. AviadoBio’s clinical and preclinical pipeline spans frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), inherited retinal diseases, and tauopathies, including Alzheimer’s disease.
Company HQ City:
London
Company HQ State:
E14 5GX
Company HQ Country:
United Kingdom
Year Founded:
2019
Lead Product in Development:
AVB-101 -Our lead program, gene therapy being developed for people living with frontotemporal dementia (FTD-GRN), is in Phase
1/2 clinical trial in UK, Europe, USA, Canada.
CEO
Lisa Deschamps, CEO
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
Three
When you expect your next catalyst update?
2026
What is your next catalyst (value inflection) update?
Series C funding
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}